Key result
RESTORE DEB trial tests non-inferiority against SeQuent Please for coronary in-stent restenosis.
Why the study?
Clinical information comparing the safety and efficacy of the novel RESTORE DEB versus the approved SeQuent Please DEB for coronary ISR treatment in Chinese patients is limited.
Does the RESTORE paclitaxel-coated balloon reduce in-segment late loss non-inferiorly compared to the SeQuent Please balloon in Chinese patients with coronary in-stent restenosis?
RCT (n=240)
Open-label
Central randomization via IWRS, stratified by diabetes status
Yes
Does the RESTORE paclitaxel-coated balloon reduce in-segment late loss non-inferiorly compared to the SeQuent Please balloon in Chinese patients with coronary in-stent restenosis?
Answers are grounded in this paper and cite their sources.
This study protocol outlines a randomized trial to determine if the novel RESTORE drug-eluting balloon is non-inferior to the SeQuent Please balloon for treating coronary in-stent restenosis.
In-stent restenosis (ISR), characterized by neointimal proliferation and/or neoatherosclerosis in the vessel of the stent, can cause a reduction in lumen diameter after stent implantation, which can directly induce the recurrence of angina symptoms or an acute coronary syndrome in patients and is usually life-threatening.[1]–[3] ISR has also been considered as formidable clinical problem for the interventional cardiologists. In recent years, many remarkable improvements in medical technology of percutaneous coronary intervention (PCI), such as first-generation bare metal stents (BMS) and newer-generation drug-eluting stents (DES) have been achieved, which significantly reduce ISR occurrence in patients with PCI.[4],[5] For example, growing evidence has suggested that the safety and efficacy of revascularization procedures of newer-generation DES was greatly superior to those of first generation DES and BMS.[6]–[10] However, ISR rate remains as high as 5% to 10% for patients treated with newer-generation DES at two years.[11] More recently, a newly developed drug-eluting balloon (DEB) coated with paclitaxel, an antiproliferative drug that could inhibit neointimal hyperplasia, had emerged as an alternative therapeutic tool for ISR disease.[12],[13] DEB plays the anti-restenosis efficacy through a high-concentration, rapid local delivery of paclitaxel without the use of polymers on a stent. To date, there are numerous randomized trials performed to compare the safety and efficacy among plain old balloon angioplasty (POBA), DES and DEB for the treatment of ISR.[14] One recent meta-analysis enrolled eight randomized controlled trials and indicated that DEB was a better option for treatment of ISR when compared to POBA.[15] Another meta-analysis showed that DEB and DES have similar efficacy and safety for the treatment of ISR.[16] SeQuent® Please DEB is the only approved product utilized for ISR treatment in China.[17] Currently, a novel paclitaxel-coated balloon (RESTORE DEB) has been invented for the treatment of ISR. However, clinical information on the two different types of DEB in treatment of ISR is limited. This trial aims to compare the safety and efficacy of the RESTOREDEB versus SeQuent® Please DEB for the treatment of coronary ISR in Chinese patients.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2018) conducted an RCT in Coronary in-stent restenosis (n=240). RESTORE DEB vs. SeQuent Please DEB was evaluated on In-segment late loss at 9 months follow-up as measured by quantitative coronary angiography. The RESTORE drug-eluting balloon will be compared to the SeQuent Please balloon in a planned randomized controlled trial to evaluate non-inferiority for treating coronary in-stent restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: